Truist reiterates Buy on Scholar Rock stock, $77 target on launch
Truist Securities has maintained its favorable outlook on Scholar Rock (SRRK) shares, maintaining a Buy rating and raising its price target to $77.00. This revised target follows a non-deal roadshow featuring senior management, including the Chief Operating Officer, Chief Financial Officer, and Vice President of Investor Relations.
The firm's increased confidence in Scholar Rock's team's ability to execute in the rare disease space, particularly in spinal muscular atrophy (SMA) therapies, is a key driver behind this reassessment. While the company is not projected to be profitable this year, its strong current ratio of 7.02 suggests adequate liquidity to support its early launch strategies.
Truist's optimism stems from early demand indications among identified SMA patients and the cautious approach to reporting early launch metrics. Recent regulatory updates, such as Scholar Rock's resubmission of its Marketing Authorization Application for apitegromab to the European Union, have further bolstered investor interest and spurred additional ratings upgrades from other firms like Raymond James and Piper Sandler.
These developments underscore the company's strategic focus on pricing and market adoption of its innovative therapies.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
